101 Main Street
3 articles with Anthos Therapeutics
Earlier this year, BioSpace tallied up the hottest U.S. biotech start-ups in their NextGen Bio Class of 2020 – Anthos Therapeutics was ranked #2.
Anthos Therapeutics Partners with Lonza to Develop and Manufacture Abelacimab (MAA868), a Unique Dual Factor XI / XIa inhibitor
The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.